Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

<h4>Objectives</h4>The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated with TNF inhibitors.<h4>...

Full description

Bibliographic Details
Main Authors: Saara Huoponen, Kalle J Aaltonen, Jaana Viikinkoski, Jarno Rutanen, Heikki Relas, Kirsi Taimen, Kari Puolakka, Dan Nordström, Marja Blom
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0220142

Similar Items

Similar Items